[Lupus erythematosus]
- PMID: 26025373
- DOI: 10.1007/s00105-015-3644-7
[Lupus erythematosus]
Abstract
Background: Lupus erythematosus is an autoimmune disease with a broad spectrum of cutaneous manifestations. The pathogenesis of lupus is based on a loss of tolerance against self antigens and can be mediated by defects in apoptosis, defects in eliminating cellular remnants and increased activation of the innate as well as the adaptive immune system. The increased activation of the innate immune system can be mediated by sensing of endogenous or exogenous nucleic acids, genetic variants in the components of the receptor cascade or disturbances in restriction of self nucleic acids. The inflammatory milieu is characterized by type I interferon expression and autoantibody production. The main trigger factors of the disease are sun exposure and viral infections.
Treatment: Lupus erythematosus is effectively treated by glucocorticosteroids. Approved alternatives for long-term treatment are antimalarial agents and the B-cell inhibitor belimumab for patients with systemic lupus erythematosus.
Conclusion: Future studies should more intensely analyse the effect of novel therapies on cutaneous manifestations to allow early detection of cutaneous lupus. Furthermore novel therapeutic strategies which specifically target the responsible pathogenetic mechanisms of the individual subtypes of lupus erythematosus are needed to improve the therapeutic success for this heterogeneous patient population.
Similar articles
-
Management of non-renal non-neurologic persistent lupus activity in real world patients from Argentina.Lupus. 2019 Aug;28(9):1167-1173. doi: 10.1177/0961203319861687. Epub 2019 Jul 12. Lupus. 2019. PMID: 31299882
-
[Skin manifestations in lupus erythematosus: clinical aspects and therapy].Z Rheumatol. 2011 Apr;70(3):213-26; quiz 227. doi: 10.1007/s00393-011-0789-3. Z Rheumatol. 2011. PMID: 21494937 German.
-
The different faces of cutaneous lupus erythematosus.G Ital Dermatol Venereol. 2009 Apr;144(2):135-47. G Ital Dermatol Venereol. 2009. PMID: 19357621 Review.
-
Management of "refractory" skin disease in patients with lupus erythematosus.Best Pract Res Clin Rheumatol. 2005 Oct;19(5):767-84. doi: 10.1016/j.berh.2005.05.003. Best Pract Res Clin Rheumatol. 2005. PMID: 16150402 Review.
-
[Cutaneous lupus erythematosus and skin manifestations in systemic lupus erythematosus].Z Rheumatol. 2013 Jun;72(5):429-35. doi: 10.1007/s00393-013-1134-9. Z Rheumatol. 2013. PMID: 23743985 German.
Cited by
-
[Molecular diagnosis of collagen vascular diseases and vasculitides].Hautarzt. 2016 Jan;67(1):40-52. doi: 10.1007/s00105-015-3728-4. Hautarzt. 2016. PMID: 26650868 Review. German.
-
[37-year-old male with confluent papules and arcuate erythematosquamous plaques on the upper trunk and arms : Preparation for the specialist examination: part 22].Hautarzt. 2018 Nov;69(Suppl 2):173-176. doi: 10.1007/s00105-018-4297-0. Hautarzt. 2018. PMID: 30374546 German. No abstract available.
-
Course and outcome of chilblain-like acral lesions during COVID-19 pandemic.J Eur Acad Dermatol Venereol. 2023 Jan;37(1):e29-e31. doi: 10.1111/jdv.18582. Epub 2022 Oct 1. J Eur Acad Dermatol Venereol. 2023. PMID: 36149533 Free PMC article. No abstract available.
-
[Involvement of mucous membranes in autoimmune bullous diseases].Hautarzt. 2016 Oct;67(10):774-779. doi: 10.1007/s00105-016-3871-6. Hautarzt. 2016. PMID: 27631412 Review. German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical